The Role of Tumour Metabolism in Cisplatin Resistance

被引:74
作者
Wang, Lude [1 ]
Zhao, Xiaoya [1 ]
Fu, Jianfei [2 ]
Xu, Wenxia [1 ]
Yuan, Jianlie [3 ]
机构
[1] Zhejiang Univ, Affiliated Jinhua Hosp, Cent Lab, Sch Med, Jinhua, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Med Oncol, Sch Med, Jinhua, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Neurosurg, Sch Med, Jinhua, Zhejiang, Peoples R China
关键词
tumour metabolism; cisplatin; resistance; DNA damage repair; ROS; CELL LUNG-CANCER; PHASE-III TRIAL; REPROGRAMMING GLUCOSE-METABOLISM; PLUS CISPLATIN; GASTRIC-CANCER; OPEN-LABEL; MULTIDRUG-RESISTANCE; GLUTAMINE-METABOLISM; MOLECULAR-MECHANISMS; SERINE METABOLISM;
D O I
10.3389/fmolb.2021.691795
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cisplatin is a chemotherapy drug commonly used in cancer treatment. Tumour cells are more sensitive to cisplatin than normal cells. Cisplatin exerts an antitumour effect by interfering with DNA replication and transcription processes. However, the drug-resistance properties of tumour cells often cause loss of cisplatin efficacy and failure of chemotherapy, leading to tumour progression. Owing to the large amounts of energy and compounds required by tumour cells, metabolic reprogramming plays an important part in the occurrence and development of tumours. The interplay between DNA damage repair and metabolism also has an effect on cisplatin resistance; the molecular changes to glucose metabolism, amino acid metabolism, lipid metabolism, and other metabolic pathways affect the cisplatin resistance of tumour cells. Here, we review the mechanism of action of cisplatin, the mechanism of resistance to cisplatin, the role of metabolic remodelling in tumorigenesis and development, and the effects of common metabolic pathways on cisplatin resistance.
引用
收藏
页数:13
相关论文
共 144 条
[31]   Systems biology of cisplatin resistance: past, present and future [J].
Galluzzi, L. ;
Vitale, I. ;
Michels, J. ;
Brenner, C. ;
Szabadkai, G. ;
Harel-Bellan, A. ;
Castedo, M. ;
Kroemer, G. .
CELL DEATH & DISEASE, 2014, 5 :e1257-e1257
[32]   Molecular mechanisms of cisplatin resistance [J].
Galluzzi, L. ;
Senovilla, L. ;
Vitale, I. ;
Michels, J. ;
Martins, I. ;
Kepp, O. ;
Castedo, M. ;
Kroemer, G. .
ONCOGENE, 2012, 31 (15) :1869-1883
[33]  
Gan XF, 2014, INT J CLIN EXP MED, V7, P2530
[34]   The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance [J].
Giacomini, Isabella ;
Ragazzi, Eugenio ;
Pasut, Gianfranco ;
Montopoli, Monica .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
[35]   Is cisplatin-induced cell death always produced by apoptosis? [J].
Gonzalez, VM ;
Fuertes, MA ;
Alonso, C ;
Perez, JM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :657-663
[36]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[37]   Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? [J].
Hay, Nissim .
NATURE REVIEWS CANCER, 2016, 16 (10) :635-649
[38]   Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin [J].
Holzer, Alison K. ;
Manorek, Gerald H. ;
Howell, Stephen B. .
MOLECULAR PHARMACOLOGY, 2006, 70 (04) :1390-1394
[39]   Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System [J].
Hong, Weipeng ;
Cai, Peiheng ;
Xu, Chuncao ;
Cao, Di ;
Yu, Weibang ;
Zhao, Zhongxiang ;
Huang, Min ;
Jin, Jing .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[40]   COMBINED RADIATION AND CHEMOTHERAPY FOR INVASIVE TRANSITIONAL-CELL CARCINOMA OF THE BLADDER - A PROSPECTIVE-STUDY [J].
HOUSSET, M ;
MAULARD, C ;
CHRETIEN, Y ;
DUFOUR, B ;
DELANIAN, S ;
HUART, J ;
COLARDELLE, F ;
BRUNEL, P ;
BAILLET, F .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2150-2157